Delivra Health Brands (DHB) AI Stock Analysis

• Market Cap: C$5.78M
• Dividend Yield: N/A
• Average Volume (3M): 26.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: 13.01%
• EPS Growth: -2445.45%
• Country: CA
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 31,261,782
• 10 Day Avg. Volume: 58,945
• 30 Day Avg. Volume: 26,134
• PEG Ratio: 0.02
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 0.41
• P/FCF Ratio: -7.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.73
• Price Target Upside: 284.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: C$0.20 ▲(4.21% Upside)

The score is primarily weighed down by weak financial quality—ongoing losses and negative operating/free cash flow despite strong revenue growth and solid gross margins. Technicals are also bearish with the stock trading below major moving averages and a negative MACD, while valuation signals are limited due to a negative P/E and no dividend support.

Positive Factors

Revenue Growth

A 28.4% revenue growth rate indicates strong market demand and effective sales strategies, supporting long-term business expansion and sustainability.

Strategic Partnerships

The QVC partnership enhances distribution and brand visibility, potentially increasing market share and consumer engagement in the U.S. market.

Cash Flow Improvements

Improved cash flow indicates better operational efficiency and financial health, providing the company with greater liquidity and flexibility for future investments.

Negative Factors

Negative EBIT Margins

Negative EBIT margins suggest challenges in covering operating costs, which can hinder profitability and limit reinvestment capacity for growth.

Low Net Profitability

Low net profitability limits the company's ability to generate sufficient returns, affecting its long-term financial sustainability and shareholder value.

Minimal Return on Equity

Minimal return on equity indicates inefficiency in using shareholder funds to generate profits, potentially impacting investor confidence and capital attraction.

Delivra Health Brands Business Overview & Revenue Model

Company Description

Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. The company is involved in selling of cannabis, liquid sleep shots, sleep powder packets, gummies, and pain relief creams. It offers its products under LivRelief, Dream Water, and LivRelief infused brand names. The company was formerly known as Harvest One Cannabis Inc. Delivra Health Brands Inc. is headquartered in Vancouver, Canada.

How the Company Makes Money

Delivra Health Brands generates revenue primarily through the sale of its topical products, which are distributed across various retail and online channels. The company capitalizes on its proprietary delivery systems to offer differentiated products that appeal to consumers seeking effective health and wellness solutions. Additionally, DHB may engage in strategic partnerships or licensing agreements with other companies to expand its market reach and enhance its product offerings. These collaborations can contribute to revenue generation by enabling access to new markets and customer segments.

Delivra Health Brands Financial Statement Overview

Summary

Strong TTM revenue growth (+32.9%) and solid gross margin (~49.8%) are positives, and leverage is manageable (debt-to-equity ~0.50). However, the company is loss-making (net margin ~-6.0%), EBITDA margin is thin (~2.8%), and cash flow is the key weakness with negative operating/free cash flow (about -$0.68M), raising near-term funding risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue grew strongly (+32.9%) and gross margin is solid (~49.8%), showing improving scale and product economics versus earlier years. However, profitability remains weak: the company is still loss-making (net margin about -6.0%) with slightly negative operating profit, and EBITDA margin is thin (~2.8%). The earnings trajectory is mixed—profitable in FY2024 but back to losses in FY2025/TTM—suggesting inconsistent operating execution.

Balance Sheet

Leverage looks manageable with debt at roughly half of equity in TTM (debt-to-equity ~0.50), and equity remains positive, providing some balance-sheet cushion. That said, returns to shareholders are currently negative (TTM return on equity ~-18.9%), reflecting ongoing losses, and assets have trended down from prior years, which can limit financial flexibility if the turnaround takes longer than expected.

Cash Flow

Cash generation is the key weak spot: TTM operating cash flow and free cash flow are both negative (about -$0.68M), and free cash flow deteriorated versus the prior period. While FY2024 showed positive cash flow, the recent reversion to cash burn raises near-term funding risk and makes the path to self-funding operations less certain.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.41M	13.37M	12.38M	9.79M	8.14M	7.96M
Gross Profit	6.68M	6.78M	6.40M	3.49M	485.00K	-297.00K
EBITDA	369.00K	427.00K	2.35M	1.40M	-4.25M	-7.04M
Net Income	-806.00K	-1.19M	876.00K	-184.00K	-7.01M	-28.54M
Balance Sheet
Total Assets	9.09M	9.61M	10.05M	10.56M	11.59M	19.06M
Cash, Cash Equivalents and Short-Term Investments	3.25M	3.30M	4.20M	2.73M	1.11M	5.14M
Total Debt	2.19M	2.11M	2.03M	1.96M	2.11M	2.16M
Total Liabilities	4.76M	5.37M	4.86M	7.17M	8.21M	9.09M
Stockholders Equity	4.33M	4.24M	5.19M	3.39M	3.37M	9.98M
Cash Flow
Free Cash Flow	-677.00K	-754.00K	756.00K	-1.13M	-4.46M	-9.68M
Operating Cash Flow	-677.00K	-754.00K	756.00K	-1.09M	-4.44M	-9.65M
Investing Cash Flow	0.00	0.00	11.00K	2.91M	1.35M	12.27M
Financing Cash Flow	-25.00K	-36.00K	594.00K	-255.00K	-309.00K	446.00K

Delivra Health Brands Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHB, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.22, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.94 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DHB.

Delivra Health Brands Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TGIF	50 Neutral	C$4.96M	9.09	―	―	-2.30%	―
PCLO	44 Neutral	C$12.31M	-2.23	―	―	15.64%	58.47%
DHB	43 Neutral	C$5.78M	-7.17	-17.81%	―	13.01%	-2445.45%
CDVA	41 Neutral	C$2.20M	-0.76	―	―	1.60%	-213.10%

Delivra Health Brands Corporate Events

Delivra Health Brands Reports Q1 2026 Growth in Dream Water® and LivRelief™

Delivra Health Brands reported financial results for the first quarter of fiscal 2026, highlighting growth in its core products, Dream Water® and LivRelief™. Dream Water® saw an 8% increase in sales in the US and Canada and a 74% rise in e-commerce sales, while LivRelief™ experienced a 9% growth in sales and a 16% increase in e-commerce. Despite a temporary reduction in the licensed LivRelief™ Infused segment, the company remains optimistic about future growth. The company’s net revenue increased by 1% compared to the same period last year, with a positive adjusted EBITDA driven by increased sales volume and reduced marketing expenses. Delivra Health plans to expand its market coverage and secure new retail partners in the second half of fiscal 2026.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.77 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.